le pdf qui fache --------->
Auj. à 07:24
Also in March, NicOx began proof-of-concept trials of
NCX-6560 for the potential treatment of cardiovascular
disease. The drug is a modified, NO-releasing version of
atorvastatin (Pfizer’s Lipitor®), and follows the company’s
previous investigations of pravastatin (Bristol-Myers Squibb’s
Pravachol®) and fluvastatin (Novartis’s Lescol®), bound to an
NO-releasing moiety, for the same indications.
The study is in three parts. In the first, 40 healthy males will
receive single-escalating doses of NCX-6560 or placebo. In the
second, 48 subjects with high levels of low-density lipoprotein
cholesterol will receive NCX-6560, atorvastatin or placebo.
Finally, 10 healthy males who received the highest tolerated dose
in the first part of the study will receive NCX-6560 or placebo
following a high-fat breakfast.
At the end of these trials, NicOx hopes to have established
the candidate’s safety, tolerability, pharmacokinetics and
pharmacodynamics. It intends also to evaluate a biomarker
relevant to cardiovascular disorders, helping researchers to
guide future development of the drug.
Of special interest here will be NCX-6560’s performance against
Lipitor, the largest grossing drug in the world with sales of
US$13.5 billion in 2007. Preclinical studies showed that both
drugs had a similar effect at lowering lipids, but NCX-6550
had superior anti-platelet and anti-inflammatory activity, and
improved endothelial function.
riposto questo messaggio da mettere agli atti!!!!!!!!!!!!!!!!! Qualcuno degli eletti disfattisti mi può spiegare il perchè questo post subisce costante censura da parte di Boursorama che poi è una costola di société Génerale!!!!!!!!!!!!! Forse forse infastidisce l'accumulo per qualcuno??????????????? O voi esseri supremi del fol datemi una risposta dall'alto della vostra cultura finanziaria????????????
